1 Q1/15 – all rights reserved Zestagen S.A. Services Summary 2015 v6/Q1 15 Nassos Alevizopoulos,...

1 Q1/15 – all rights reserved

Zestagen S.A.

Services Summary

2015

v6/Q1 15

Nassos Alevizopoulos, PhD, MBA

Managing Partner

[email protected]


Meta-plasis (trans-formation) at a glance

boutique biotech & pharma consulting

Support project mgmt. or investment decisions

Sector dedication

Analyze, integrate & transform

Extreme focus on science (Medline, WIPO)

Commercial & financial info (databases)

Excellent value for money

Minuscule team (EU/US) with broad international network

Consultants with active executive roles

Direct access to specialized associated networks

We understand & get down into the project’s core science

Virtual operations (timesheet, availability)

Rapid turnaround

what we do

how we do it

why us?


Key Metaplasis people

Nassos Alevizopoulos, PhD, MBA Kostas Alevizopoulos, PhD Andrei Lyne, MBA

CH CH USA

• 20y of experience in biopharmaceutical development (large molecules, devices)

• currently CEO of Zestagen SA (preclinical cancer mAb; CH)

• oversaw an orphan drug designation in pancreatic cancer

• COO/CEO positions in various biopharma companies (US/GR)

• cofounded startup companies

• Business Planning & Analysis with Novartis

• Brunner Prize for the best of 181 PhDs in Molecular Biology (Lausanne Univ.); also MBA from Lausanne

• 17y of experience in life sciences (drug development, small molecules, diagnostics)

• currently CEO of APIM Therapeutics AS (cancer biotech, Norway)

• partner at Ventac Partners

• previously CEO/CSO/Head of R&D in various biotech companies (US/CH/GR)

• cofounded startup companies

• Ph.D. in Molecular Oncology (Univ. of Lausanne)

• trained in European patent law (Univ. of Strasbourg)

• 12y with UBS Investment Bank in London & New York, most recently as Executive Director

• over 100 transactions across 25 countries for deals worth an aggregate $8 billion;

• currently CFO at Synpromics Ltd.

• Experience in biopharma, buy-side and sell-side M&A, IPOs, convertible bonds etc.

• BA from Oxford Univ. (Baker Scholarship)

• MBA in finance from New York Univ. (Directors Fellowship)


1. Metaplasis can assist academic institutions with tech transfer

Technology appraisal

Scientific analysis

Intellectual Property / Freedom to Operate (FTO) analysis

SWOT analysis

Evaluation of partnering potential

Tech valuation

Tech agreement drafting (Sponsored Research, CRADA)

Collaboration with Univ. Tech Transfer Office (TTO)

academicdiscovery

Commercializable?

TTOTTO

Seed $angels

Spinoffformation


1. Metaplasis can assist academic institutions with tech transfer (cont’ed)

Case study 1: NewCo formation around cutting-edge cancer IP

Unique mAb against cancer

IP licensed from a European Institution to NewCo

Seed investor found

Case study 2: a Scandinavian University

Position novel anti-cancer therapeutics

Case study 3: mandate from a group of Canadian investors (on going)

Scout for promising tech in N. America for NewCo formation

Case study 4: technology appraisal for a Chinese biopharma company

Report & annexes delivered in 10 business days


2. Metaplasis can assist with preclinical drug development effort

Drawing from hands-on experience (running our own companies) we can

assist with:

Preclinical development plan generation

Outsourcing decisions (chose relevant Contract-Research Organizations)

Scientific & regulatory preparation for Guidance Regulator meetings (Scientific

Advice, Protocol Assistance, IND/IMPD)

Case studies

Assist a clinical CRO to attract an assignment by a vaccine developer

for preclinical regulatory assistance


Sample Preclinical

Development Plan

Time

Actions

Cost

Incumbent

Single Page format

2. Metaplasis can assist with preclinical drug development effort (cont’ed)


3. Metaplasis can assist with investment decisions

Product/company

valuations

risk-adjusted

NPV

comparables

EV/EBITDA

Case study 1:

Estimate value of a

Scandinavian

biotech company

with rNPV

Case study 2

EV/EBITDA analysis

of a Greek

healthcare takeover

target

c2: EV/EBITDA

c1: rNPV


4. Metaplasis can assist with business development of market-ready products

Strategy development for market-ready (i.e. approved) products entering new

geographic markets

Identification of potential partners (licensors, buyers/sellers)

Development of client company materials (non-conf & conf)

Deal Structures & Value Sharing (e.g. up-fronts vs. delayed payments)

Network in Balkans, MENA, CIS, some EU countries, some States

pharmaceuticals, medical devices, neutraceuticals, herbals


Case: ranking candidate Greek distributors for an Asian company

4. Metaplasis can assist with business development of market-ready products (c’ed)


Summary of Metaplasis Services

1. Technology appraisals (academic institutions, biotech, investors…)

2. Assistance with preclinical drug development (biotech)

3. Assistance with investment decisions (biotech, investors)

4. Business development (market-ready products for pharma, devices etc.)


Zestagen S.A.

Thank You

Nassos Alevizopoulos, PhD, MBA

Managing Partner

[email protected]

1 Q1/15 – all rights reserved Zestagen S.A. Services Summary 2015 v6/Q1 15 Nassos Alevizopoulos,...

Documents

Transcript of 1 Q1/15 – all rights reserved Zestagen S.A. Services Summary 2015 v6/Q1 15 Nassos Alevizopoulos,...